Thermo Fisher Scientific today announced the availability of the Oncomine™ Comprehensive Assay Plus on the Ion Torrent™ Genexus™ System, marking a significant advancement in accelerating precision oncology research. This powerful combination enables researchers to perform comprehensive genomic profiling (CGP) and obtain results as soon as the next day—streamlining workflows through the Genexus System’s fully automated, end-to-end capabilities.
The Oncomine Comprehensive Assay Plus is designed to detect a wide array of genomic alterations across 517 genes, including single-nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), and gene fusions. In addition, it identifies crucial genomic signatures such as tumor mutational burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD). These features make it a robust tool for uncovering oncogenic drivers and facilitating in-depth cancer profiling.
While already in use on the Ion GeneStudio™ S5 Systems, the assay’s integration with the Genexus System significantly reduces time-to-results. With its simplified, automated process requiring minimal hands-on time, the Genexus System enables labs with varying levels of NGS expertise to conduct sophisticated genomic analysis quickly and efficiently.
“Having access to a complete, rapid CGP solution that includes all critical biomarkers like TMB, MSI, and HRD is a breakthrough,” said Hector M. Alcaraz, MS, Founder of Imagene Health, SA de CV. “This innovation will help democratize CGP in our region and drive momentum in precision medicine.”
The Genexus System is recognized for its automation and integration, enabling next-generation sequencing (NGS) results within a single day. By pairing this capability with the Oncomine Comprehensive Assay Plus, research institutions can accelerate their oncology research programs, from biomarker discovery to therapy development.
Kathy Davy, President of Clinical Next-Generation Sequencing at Thermo Fisher Scientific, commented on the broader impact: “In recent years, genomic insights have become central to our understanding of disease and have spurred innovation in drug development. With the Oncomine Comprehensive Assay Plus now available on the Genexus System, we are bringing the speed and depth of rapid CGP to more laboratories, empowering researchers to generate meaningful data faster and furthering potentially life-saving scientific breakthroughs.”
This development reflects Thermo Fisher’s ongoing commitment to making high-quality genomic research tools more accessible, enabling faster, data-driven progress in cancer research and personalized medicine.